Studies are beginning to emerge that demonstrate intriguing differences between human-induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs). Here, we investigated the expression of key members of the Nodal embryonic signaling pathway, critical to the maintenance of pluripotency in hESCs. Western blot and real-time RT-PCR analyses reveal slightly lower levels of Nodal (a TGF-b family member) and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitor and TGF-b family member) in hiPSCs compared with hESCs. The noteworthy drop in hiPSC's Lefty expression correlated with an increase in the methylation of Lefty B CpG island. Based on these findings, we addressed a more fundamental question related to the consequences of epigenetically reprogramming hiPSCs, especially with respect to maintaining a stable ESC phenotype. A global comparative analysis of 365 microRNAs (miRs) in two hiPSC versus four hESC lines ultimately identified 10 highly expressed miRs in hiPCSs with >10-fold difference, which have been shown to be cancer related. These data demonstrate cancer hallmarks expressed by hiPSCs, which will require further assessment for their impact on future therapies.
The technologies developed to produce human-induced pluripotent stem cells (hiPSCs), derived by epigenetic reprogramming of human fibroblasts, have provided an exciting new platform for generating dedifferentiated somatic cellsthought to be almost identical to human embryonic stem cells (hESCs) (Yu et al., 2007) and of great promise for patienttailored regenerative medicine therapies. However, recent reports are beginning to highlight noteworthy differences in gene expression signatures (Chin et al., 2009 ) and differential DNA methylation patterns (Doi et al., 2009 ) between these two stem cell types that collectively prompt additional comparative analyses. Equally important is the challenge we face in the scientific community promoting the use of embryonic stem cells, for regenerative medicine therapies, fully recognizing their tumorigenic potential in immunocompromised mouse models and our lack of understanding how to regulate normal pluripotency and differentiation over tumorigenic potential (reviewed by Knoepfler, 2009) . Therefore, the aim of our study was to initially assess the expression levels of three major components of the embryonic Nodal signaling pathway, which is of critical significance in stem cell pluripotency and differentiation (Schier, 2003) . Nodal is a member of the TGF-b family and an important morphogen and regulator of cell fate in embryological systems and requires tight control of its biological function (Schier and Shen, 2000) . Extracellular Nodal inhibitors, such as Lefty A and Lefty B (divergent members of the TGF-b family), control Nodal signaling by binding directly to Nodal, or by binding to Cripto-1 (Nodal's co-receptor and a member of the Epidermal Growth Factor-Cripto-1/FRL-1/Cryptic [EGF-CFC] family). Our results demonstrate lower levels of Nodal (a TGF-b family member) and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitor and TGF-b family member) in hiPSCs compared with hESCs (with an accompanying increase in the methylation of Lefty B CpG island). Based on these findings, the second part of our study addressed the implications associated with the epigenetic reprogramming of hiPSCs, consisting of a global comparative analysis of 365 microRNAs (miRs) in hiPSC versus hESC lines. The data reveal 10 highly expressed miRs in hiPSCs with >10-fold difference, which have been shown to be cancer related, thus serving as a catalyst for further assessment with respect to their clinical use in regenerative medicine.
Materials and Methods

Cells and culture
Two hiPSC cultures IMR90-1, Madison, WI) and four hESC cultures H7, H14 (WiCell) and CM7, CM14, established at CMRC (Laurent et al., 2010) , (currently pending approval for addition to the NIH Stem Cell Registry) were used for this study. The cells were grown in StemPro medium (Invitrogen, Carlsbad, CA) on a Matrigel substrate (BD Bioscience, San Jose, CA). The cultures were split mechanically using the StemPro EZ Passage tool (Invitrogen). For miR analysis, confluent cultures were lifted using trypsin and then washed in ice-cold PBS and pellet stored at À808C.
Western blot, real-time RT-PCR, and DNA methylation analyses
Thirty micrograms of total cell lysate from hiPSCs or hESCs were loaded per lane in pairs onto a 4-12% Tris-Bis SDS-PAGE (Invitrogen). After transblotting onto an Immobilon membrane (Millipore, Billerica, MA), the membrane was cut into thirds and each section probed for either Nodal (antibody Clone EP2058Y; Epitomics, Burlingame, CA), Lefty (antibody AF746; R&D Systems, Minneapolis, MN) or Cripto-1 (antibody 600-401-997; Rockland, Gilbertsville, PA). The membranes were then stripped and reprobed for actin (antibody MAB1501; Millipore) as a protein loading control. For real-time RT-PCR, RNA was isolated using TRizol reagent (Invitrogen) and 1 mg reverse transcribed as previously described (Postovit et al., 2008) . Real-time RT-PCR was performed as described (Postovit et al., 2008) using TaqMan (Applied Biosystems, Carlsbad, CA) gene expression human primer/probe sets for Nodal (Hs00250630.s1), Lefty (Hs009996632.g1) and Cripto-1 (Hs02339499.g1) and gene levels normalized using HPRT-1 (433768F). Data were analyzed using Applied Biosystems' Sequence Detection Software (V. 1.2.3) and error bars represent mean gene expression normalized to hESC values, AESD. DNA from hiPSCs and hESCs was extracted by phenol-chloroform, bisulfite converted and sequenced for the Lefty B gene CpG island as previously reported (Costa et al., 2009 ).
Six to ten positive clones were sequenced and percentages of DNA methylation were calculated.
miR analysis
Total mRNA isolation from the cell lines was performed with the PureZOL RNA isolation reagent (Bio-Rad, Hercules, CA), according to the manufacturer's instructions. TaqMan LowDensity Arrays (TLDA Human MicroRNA Panel v1.0) were used to detect and quantify mature miRs in accordance with the manufacturer's instructions (Applied Biosystems' 7900 HT Micro Fluidic Cards). The cards were processed in the ABI 7900 HT Fast Real Time PCR System (Applied Biosystems) and analyzed with Real-Time StatMiner (Integromics, Philadelphia, PA). The difference in miR expression between hiPSCs and hESCs was calculated by the comparative 2
ÀDDCt method with RNU44 and RNU48 as endogenous controls (Livak and Schmittgen, 2001 ) ( P < 0.05 was considered as significant). Hierarchical clustering was performed by the Ward's method using Pearson's correlation for miR similarity measure. miRs with DCt <5 (RNU48 as endogenous controls) were considered to be at high level of expression.
To verify the accuracy of our TLDA data, we performed individual qRT-PCR experiments for representative miRs using TaqMan miR assays (Applied Biosystems) in triplicates, according 
JOURNAL OF CELLULAR PHYSIOLOGY C A N C E R H A L L M A R K S I N I N D U C E D P L U R I P O T E N T C E L L S
to the manufacturer's instructions (RNU48 as endogenous controls). miR expression levels were analyzed as above and the miRs were confirmed to be significantly up-regulated in the hiPSC compare to the hESC lines by the individual qRT-PCR experiments.
Results and Discussion
This study initially performed a comparative analysis of the major components of the embryonic Nodal signaling pathway in hESCs and hiPSCs. Western blot and real-time RT-PCR results reveal slightly lower levels of Nodal (a TGF-b family member) and Cripto-1 (Nodal's co-receptor) and a dramatic decrease in Lefty (Nodal's inhibitor and TGF-b family member) in hiPSCs compared with hESCs (Fig. 1A) . Based on the unanticipated noteworthy drop in hiPSC's Lefty expression, we performed DNA sequence-based methylation analysis of Lefty B CpG island and found increased methylation (Fig. 1A) , suggesting silencing of this critical regulator of Nodal. The implications associated with a significantly lower level of Lefty expression in hiPSCs versus hESCs, together with our earlier findings of the reemergence of aberrant Nodal signaling in metastatic tumor cells in the absence of Lefty (Postovit et al., 2008) , prompted us to address a more fundamental question focused on the implications associated with the epigenetic reprogramming of hiPSCs, particularly related to the fidelity of these cells to maintain a stable ESC phenotype.
We pursued a comparison of the expression profiles of 365 miRs in two hiPSC (fibroblasts reprogrammed with Oct4, Sox2, Nanog, and Lin28) and four hESC lines, recognizing that specific miRs are known to be associated with oncogenic pathways (Tong et al., 2009) . Although the ability of hESCs and hiPSCs to form teratomas in immunocompromised mice is well documented (Thomson et al., 1998; Yu et al., 2007) , particularly noteworthy are the observations in chimeric mice derived from iPSCs generated with exogenous c-myc, where malignant tumors developed in up to 20% of the mice (Okita et al., 2007) versus mice derived from iPSCs reprogrammed without exogenous c-myc, where no tumors have been reported (Wernig et al., 2008) . These disparate findings prompted further inquiry into the potential pathways employed by normal cells resulting in pluripotency versus oncogenic transformation.
An unsupervised hierarchical clustering analysis of 157 miRs that were expressed in at least one of the six cell lines tested (Fig. 1B-1 ) revealed 72 miRs expressed at statistically different levels in hiPSCs versus hESCs ( P < 0.05), 31 exhibiting greater than 10-fold difference ( Fig. 1B-2 ; Table 1 ). Further statistical analysis of the 31 miRs indicated that 15 were expressed at high levels (DCt <5), 10 of which have been shown to be cancer related (Fig. 1B-3) . Specifically, differential expression of these 10 miRs has been shown to regulate critical checkpoints in Hodgkin's lymphoma, multiple myeloma, and breast, pancreatic and prostatic carcinoma (Mertens-Talcott et al., 2007; Pichiorri et al., 2008; Yan et al., 2008; Gibcus et al., 2009; Tong et al., 2009; Greither et al., 2010) . The miR differences found in this study between hiPSCs and hESCs further support the recent findings of Doi et al. (2009) , who indicated that the target loci involved in epigenetic reprogramming to pluripotency parallels aberrant oncogenic transformation programming, and advances the observations of Feng et al. (2010) reporting early senescence of hiPSCs derivatives. Our investigation also revealed that both hiPSCs fibroblasts-isolated from either fetal origin (IMR90) or newborn foreskin hiPSCs resulted in a similar miR expression profile between them as did hESCs miR expression among cell lines of different ethnic origin. Collectively, these data demonstrate cancer hallmarks expressed by hiPSCs, which will require further elucidation for their impact on clinical applications, especially with respect to the fate of precancerous stem cells. Cancer related miRs from Figure 1B -3 are in bold. a hiPSC Foreskin-1. b hiPSC IMR90-1.
